Octocrylene

Summary

Octocrylene (CHEMBL1201147) is an approved small molecule; indicated across 1 condition.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 1 condition
• Chemistry: 361.5 Da · C24H27NO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201147
Name	Octocrylene
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	22571
Molecular formula	C24H27NO2
Molecular weight	361.5
InChIKey	FMJSMJQBSVNSBF-UHFFFAOYSA-N

SMILES: CCCCC(CC)COC(=O)C(=C(C1=CC=CC=C1)C2=CC=CC=C2)C#N

IUPAC name: 2-ethylhexyl 2-cyano-3,3-diphenylprop-2-enoate

Also known as: NSC-760433, Octocrilene, Octocrileno, Octocrylene, Octocrylene component of anthelios sx, Octocrylene component of capital soleil, SID17389332, SID29215118, SID85147156, OCTOCRYLENE, SID144204704, SID144207434

Patent coverage: 11,613 distinct patent families (34,935 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Nuclear receptor ROR-gamma, Prelamin-A/C, Cruzipain, Aldehyde dehydrogenase 1A1, Mitogen-activated protein kinase 1, Lethal factor.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 6 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P15917	5.6	Potency	2512	nM	CHEMBL_ACT_4659349
LMNA	5.3	Potency	5012	nM	CHEMBL_ACT_3639106

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).